Pharmaceuticals — Investor's Playbook
India is the "pharmacy of the world" — supplying 20% of global generic drug volume, 60% of global vaccine supply, and 40% of US generic drug demand. The Indi...
India is the "pharmacy of the world" — supplying 20% of global generic drug volume, 60% of global vaccine supply, and 40% of US generic drug demand. The Indian pharma sector generates $50B+ in revenue, with listed players ranging from global generics giants (Sun Pharma, Dr. Reddy's) to domestic-focused formulation companies (Mankind, Alkem) to API manufacturers (Divi's, Laurus Labs).
Sector Map
Key Players
| Company | Revenue (₹ Cr) | Focus | EBITDA Margin | Market Cap |
|---|---|---|---|---|
| Sun Pharmaceutical | 50,000+ | US generics + specialty + India | 28-32% | ₹4L+ Cr |
| Dr. Reddy's Labs | 28,000+ | US generics + biosimilars | 25-28% | ₹1L+ Cr |
| Cipla | 25,000+ | India + US + emerging markets | 22-26% | ₹1.2L+ Cr |
| Divi's Laboratories | 8,000+ | API + CRAMS (pure play) | 32-38% | ₹1L+ Cr |
| Mankind Pharma | 12,000+ | India domestic (mass market) | 22-26% | ₹1L+ Cr |
| Torrent Pharmaceuticals | 11,000+ | India chronic + US | 28-32% | ₹70,000+ Cr |
| Lupin | 20,000+ | US + India | 20-24% | ₹70,000+ Cr |
| Laurus Labs | 6,000+ | API + CDMO | 20-28% (volatile) | ₹30,000+ Cr |
Learning Path
| # | Lesson | Focus Area |
|---|---|---|
| 1 | Industry Overview | India's pharma edge, segments, regulatory |
| 2 | Key Metrics | R&D spend, ANDA pipeline, MR productivity |
| 3 | Competitive Landscape | Sun vs Cipla vs Dr. Reddy's vs domestic |
| 4 | Risks & Red Flags | USFDA, price erosion, patent cliffs |
| 5 | Valuation Framework | PE, pipeline value, CDMO premium |
The Two Pharma Stories
India pharma has TWO distinct investment stories: (1) Domestic branded generics — FMCG-like compounders (Mankind, Torrent) with 15-18% growth, stable margins, no FDA risk. (2) US generics/CDMO — high growth potential but volatile (Sun, Lupin, Laurus) with FDA risk, pricing pressure, and lumpy Para-IV gains. Your risk appetite determines which story to play.
1. Pharmaceuticals — Industry Overview
India's Pharma Market Segments
| Segment | Size (India) | Growth | Key Players |
|---|---|---|---|
| Domestic formulations (branded generics) | ₹2L+ Cr | 8-12% | Mankind, Cipla, Sun, Torrent, Alkem |
| US generics (ANDA-based exports) | $15B+ exports | 5-10% (variable) | Sun, Dr. Reddy's, Aurobindo, Lupin |
| API / bulk drugs | ₹1.2L Cr | 10-14% | Divi's, Laurus, Solara, Aarti Drugs |
| CRAMS / CDMO | ₹30,000+ Cr | 18-25% | Syngene, Divi's, Piramal, Laurus |
| Biosimilars | ₹10,000+ Cr | 20-30% | Biocon, Dr. Reddy's, Cipla |
| Emerging market exports | $8B+ | 10-15% | Cipla (Africa), Dr. Reddy's, Lupin |
Why India Dominates Global Generics
| Advantage | Explanation |
|---|---|
| Cost structure (30-40% cheaper) | Lower wages, infrastructure, raw material cost |
| Scale (500+ FDA-approved plants) | Largest number outside US |
| Skilled pharma workforce | Lakh+ chemistry/pharmacy graduates annually |
| ANDA filing capability | 40% of US generics are from India |
| Patent Act (process patents pre-2005) | Built reverse-engineering expertise |
| API self-sufficiency (partial) | Reducing China dependency (PLI scheme) |
Business Model Types
Regulatory Framework
| Regulator | Market | Impact |
|---|---|---|
| USFDA (USA) | US generics | Plant inspections → 483s/Warning Letters = revenue risk |
| CDSCO (India) | Domestic market | Less stringent, approvals faster |
| EMA (Europe) | EU generics | Growing market, moderate complexity |
| WHO prequalification | Emerging markets + govt tenders | Volume-based (low margin, high volume) |
Growth Drivers
| Driver | Beneficiary |
|---|---|
| Chronic disease shift (diabetes, cardiac, CNS) | India chronic-focused (Torrent, Alkem) |
| US patent cliff ($150B+ going off-patent 2024-2030) | US generics filers (Sun, Dr. Reddy's, Aurobindo) |
| China+1 in API (global diversification away from China) | Indian API companies (Divi's, Laurus) |
| CDMO growth (innovators outsourcing manufacturing) | Syngene, Divi's, Piramal |
| Domestic penetration increase (rural, tier 2-3) | Mass market (Mankind, Alkem) |
| Biosimilar opportunity ($100B+ biologics going off-patent) | Biocon, Dr. Reddy's |
Pharma Mein 2 Duniyan Hain
"Indian pharma mein do alag duniyan hain — yeh samajhna zaroori hai: (1) Domestic companies (Mankind, Torrent, Alkem) — yeh FMCG companies hain pharma ke naam pe. 10,000+ Medical Representatives (MRs) doctor ke paas jaate hain, prescription likhwate hain, branded generic bechte hain. Growth 12-15%, margins stable 22-28%, no FDA risk. Yeh predictable compounders hain. (2) US-focused companies (Sun, Lupin, Aurobindo) — yeh lumpy, volatile businesses hain. Ek ANDA approval se ₹500-1,000 Cr revenue aa sakta hai (Para-IV), par FDA warning letter se same revenue ruk sakta hai. Price erosion 5-10% annual. Big wins and big losses. Portfolio mein dono rakhne chahiye — domestic for stability, US for upside." (Two different worlds in Indian pharma — must understand: (1) Domestic companies are FMCG-like — MRs visit doctors, get prescriptions, sell branded generics. Growth 12-15%, stable margins, no FDA risk. Predictable compounders. (2) US-focused companies — lumpy, volatile. One ANDA can bring ₹500-1,000 Cr revenue, but FDA warning letter can stop same revenue. Keep both in portfolio — domestic for stability, US for upside.)
2. Pharmaceuticals — Key Metrics & KPIs
$$\text{R\&D \%} = \frac{\text{R\&D Expense}}{\text{Revenue}} \times 100$$ | Level | Company Type | What It Signals | |||| | 25% | Domesticfocused (Mankind,...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
3. Pharmaceuticals — Competitive Landscape
India's domestic pharma market is HIGHLY fragmented — top 10 players have only ~40% share. 300+ active companies. | Archetype | Companies | Strength | Risk |...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
4. Pharmaceuticals — Risks & Red Flags
| Severity Level | Description | Impact | |||| | Form 483 (observations) | Inspector finds deviations | Manageable — response + correction | | Warning Letter...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
5. Pharmaceuticals — Valuation Framework
| Archetype | Primary Metric | Typical Range | Why | ||||| | Domestic compounder (Mankind, Torrent) | PE | 3050x | Predictable growth, FMCGlike | | US generi...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.